Recently, a number of nucleotide variants have been described in the multidrug resistance 1 (MDR1/ABCB1) gene; however, most studies have focused on the coding region. In the present study, we identified promoter variants of the MDR1 gene and evaluated their phenotypic consequences using a reporter gene assay and the real-time polymerase chain reaction method. Ten allelic variants were detected in the promoter region (approximately 2 kilobases), seven of which were newly identified. Certain mutations occurred simultaneously, and a total of 10 haplotypes were observed. These promoter polymorphisms were found more frequently in Japanese than Caucasians. Some haplotypes were associated with changes in luciferase activity and placental and hepatic mRNA levels. We also determined DNA methylation status in the proximal promoter region of the MDR1 gene. The promoter region around potential binding sites for transcription factors was found to be hypomethylated and thus likely to be independent of the gene expression. Nucleotide and/or haplotype variants not only in the coding region but also in the promoter region of the MDR1 gene may be important for interindividual differences of P-glycoprotein expression.
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Polymorphisms in the genes encoding membrane transporters have recently been reported to be associated with variations in the pharmacokinetic and pharmacological effects of clinically used drugs (Fromm, 2002; Kim and Tirona, 2002; Takane et al., 2003) . Among various drug transporters, P-glycoprotein, the multidrug resistance 1 (MDR1/ABCB1) gene product, is one of the best studied. P-glycoprotein is expressed in various human tissues such as the intestine, liver, and kidney, and functions as a cellular efflux pump for foreign xenobiotics and endogenous substrates.
Although a number of nucleotide variants have been described in the MDR1 gene, most studies in this area have focused on the association of single nucleotide polymorphisms (SNPs) in the coding region with the altered expression of P-glycoprotein or pharmacokinetics of clinically used drugs. Hoffmeyer et al. (1999) demonstrated that the synonymous C3435T polymorphism (Ile1145Ile) in exon 26 was associated with a low level of expression of P-glycoprotein in the duodenum, resulting in an increase in plasma concentrations after oral administration of digoxin, used as a probe for P-glycoprotein. In contrast, higher level of duodenum P-glycoprotein expression and lower level of serum digoxin after oral administration were observed in the subjects with this variant (Sakaeda et al., 2001; Nakamura et al., 2002) . The association of the C3435T polymorphism with P-glycoprotein protein expression and function is controversial. Up to now, various investigators have reported that the variant is associated with decreased or increased expression, or it has no clearly discernible effect (Sparreboom et al., 2003; Ishikawa et al., 2004) . In a recent report, an approach using genebased haplotypes, which are specific combinations of SNPs located throughout the genome, proved superior to the use of individual SNPs for predicting the association between phenotypes and genomic variation . For example, Drysdale et al. (2000) reported that the bronchodilator response to ␤ agonist is significantly related to haplotype pairs of the ␤ 2 -adrenergic receptor gene but not to individual SNPs. With regard to the MDR1 gene, Johne et al. (2002) indicated that it was important to consider the variability in haplotype structure rather than in SNPs when characterizing the MDR1 phenotype. However, the association of variants in the promoter region of the MDR1 gene with the expression of P-glycoprotein has been not well investigated.
DNA methylation, referred to as the methylation of cytosine in a cytosine-guanosine pair (CpG), is the most common eukaryotic DNA modification and one of many epigenetic (an alteration in gene expression without a change in nucleotide sequence) phenomena (Singal and Ginder, 1999) . Normally, both the core promoter and transcriptional start site are included within the CpG-rich region, and DNA methylation regulates gene expression by interfering with the binding of specific transcription factors to their recognition sites (Singal and Ginder, 1999; Jones and Takai, 2001) . Interestingly, the human MDR1 gene has a CpG-rich promoter region. Hypomethylation of MDR1 during chemotherapy resulted in a high level of gene expression in recurrent tumors, and it had important consequences for clinical outcome in acute myeloid leukemias (Nakayama et al., 1998) and bladder cancer (Toda et al., 2000) . However, there is currently no data available on the role of DNA methylation in transcriptional regulation in normal tissues.
The aim of this study was to describe variants in the promoter region of MDR1 in Japanese and Caucasian populations and to evaluate their functional significance with regard to transcriptional activity and mRNA expression in placentas and livers obtained from Japanese subjects. Furthermore, we determined the methylation status of the promoter region of MDR1 and its association with the interindividual variability in gene expression in normal tissue.
Materials and Methods
Isolation of Genomic DNA and RNA. Human full-term placentas (highly enriched placental trophoblast populations) and livers were obtained from 96 and 19 Japanese patients, respectively. These tissues were immediately frozen in liquid nitrogen and stored at Ϫ80°C for the preparation of DNA and RNA. Blood samples were obtained from 96 healthy Caucasian volunteers. Genomic DNA from the samples was prepared using the Toyobo blood kit on a Toyobo HMX-2000 robot (Toyobo, Osaka, Japan). The isolation of genomic DNA from tissues was performed using a DNA preparation kit (QIAamp DNA mini kit; QIAGEN GmbH, Hilden, Germany). Total RNA was extracted using ISOGEN (Nippongene, Tokyo, Japan), and reverse transcription was performed with random hexamers (Promega, Madison, WI) and reverse transcriptase (Invitrogen, Carlsbad, CA). This study was approved by the Tottori University Ethics Committee, and informed consent was obtained from all individuals.
Identification of Variants in the MDR1 Promoter Region. The genotypes of MDR1 such as A-41aG, C-145G, T-129C, and C3435T were identified by PCR-restriction fragment length polymorphism analysis as described previously (Tanabe et al., 2001) . To identify unknown mutations in the MDR1 promoter region, SSCP analysis was performed using the GenePhor system (Amersham Biosciences AB, Uppsala, Sweden) as described previously (Ieiri et al., 2000) . PCR was performed in a total volume of 25 l consisting of 50 ng of genomic DNA, 10ϫ PCR buffer II, 1.5 mM MgCl 2 , 1.25 U of Amplitaq Gold DNA polymerase (Applied Biosystems, Foster City, CA), and 0.25 M of each primer. The primer sets were designed to divide the promoter region (Ϫ1700a to Ex1/ϩ88) of the MDR1 gene (GenBank accession no. AC002457) into five fragments (ϳ500 bp). After an initial denaturation at 94°C for 5 min, 45 cycles of 40 s at 94°C, 45 s at 50 to 59°C, and 1 min at 72°C, as well as a final extension period of 5 min at 72°C, were performed.
Haplotype Analysis. A 2112-bp fragment, including the promoter region of MDR1 (Ϫ1700a to Ex1/ϩ88), was amplified by using gene-specific primers (5Ј-GGAGCAAAGAAATGGAATACAATA-3Ј and 5Ј-TTCTCCCGTGAAGACCAAGTTC-3Ј). The PCR mixture was essentially the same as for the identification of mutations except for the Taq polymerase (LA Taq; Takara, Shiga, Japan). After an initial denaturation at 94°C for 5 min, 45 cycles of 40 s at 94°C, 15 s at 58.3°C, and 1 min at 72°C, as well as a final extension period of 5 min at 72°C, were performed. The PCR fragments were subcloned into pGEM-T easy vector (Promega) and sequenced.
DNA Sequence. All PCR products were sequenced directly on an ABI 377 automatic sequencer (Applied Biosystems) using a Big-Dye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems). Before the sequencing, reaction mixtures were purified with a DyeEx Spin kit (QIAGEN GmbH). The sequencing primers were those used in the PCR amplifications. The sequencing of both strands was performed for products from at least two independent PCR amplifications to ensure that the identified mutations identified were not PCR-induced artifacts.
Real-Time Quantitative PCR (TaqMan) Analysis. PCR was performed using a master mix based on the TaqMan universal PCR master mix (Applied Biosystems) and run on the ABI PRISM 7000 sequence detection system (Applied Biosystems). The following primers and TaqMan probe were used for determining the MDR1 mRNA: forward primer, 5Ј-TATCAGCAGCCCACATCATCA T-3Ј; reverse primer, 5Ј-CCAAATGTGACATTTCCTTCCA-3Ј); and probe, 5Ј-TA-CAGCACGGAAGGCCTAATGCCGA-3Ј. The endogenous reference gene was determined using the commercially available human GAPDH TaqMan Predeveloped Assay Reagent (Applied Biosystems). Each primer set and TaqMan probe were used at final concentrations of 200 and 100 nM, respectively. The reactions were run in duplicate. For all experimental samples, the amount of mRNA was determined from a standard curve (serial diluted samples from placental tissue expressed at higher levels of MDR1 and GAPDH mRNA). The mRNA level of MDR1 was expressed as a ratio to that of GAPDH.
Plasmid Construction. To obtain the first plasmid, a 2056-bp fragment (Ϫ1704a to Ex1/ϩ28) of MDR1, including the promoter region and exon 1, was initially amplified from genomic DNA with gene-specific primers incorporating 5Ј-KpnI and 3Ј-NheI, for the 5Ј end of inserts 5Ј-CGGGGTACCGGAGCAAAGAAATGGAATACA-3Ј and for the 3Ј end of inserts 5Ј-CTAGCTAGCAGTAGCTCCCAGCTT-TGCGTG-3Ј. The PCR fragment was subcloned into the pGEM-T easy vector and then introduced into competent JM109 cells (Promega). The plasmids obtained were sequenced and digested with KpnI and NheI. The digested fragment was ligated into the KpnI/ NheI site of the vector pGL3-enhancer (Promega). Manipulated DNA portions were sequenced again in their entirety.
Cell Culture and Transfection. HepG2 human hepatoma cells were incubated at 37°C under 5% CO 2 in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. One day before transfection, cells (5.5 ϫ 10 5 ) were seed into culture plates (60 mm). The cells were washed two times with serum-free medium. The luciferase reporter gene constructs (5 g) and the control reporter gene plasmid pRL-TK vector (0.5 g) (Promega) were mixed with the Tfx-20 reagent (15 l) (Promega), transferred to serum-free medium, and then incubated at room temperature for 15 min. The mixtures were added to the washed cells and incubated for 1 h at 37°C under 5% CO 2 . After the incubation, the cells were cultured in growth medium and harvested after 48 h.
Assay of Luciferase Activity. Luciferase reporter gene activity was evaluated with the Dual luciferase reporter assay system (Promega). HepG2 cells were washed once with a phosphate-buffered saline solution and lysed in passive lysis buffer (400 l). After incubation at 37°C for 15 min, lysates were mixed in a vortex blender for 15 s and centrifuged at 4°C for 30 s. Supernatants (20 l) were mixed with the luciferase reagent (100 l), and the luciferase activity was measured with a luminometer (Turner Designs, Sunnyvale, CA). After background correction (activity in untreated cells), results were expressed as the level of pGL3 activity divided by pRL activity. The total cellular protein concentration was determined using the Bio-Rad protein assay (Bio-Rad, Hercules, CA).
Electrophoretic Mobility Shift Assay (EMSA). Nuclear extracts from HepG2 cells were prepared as reported previously (Takeuchi et al., 2000) . Oligonucleotides for the MDR1 gene, including Ϫ1517a T (ACT-GTTTAGGGAGGGTTTAAGGCCATTCAAA), Ϫ1517a C (ACTGTT-TAGGGAGGGCTTAAGGCCATTCAAA), Ϫ1459a G (ATAAATGA-AAGGTGAGATAAAGCAACAAAGC), Ϫ1459a A (ATAAATGAAAG-GTGAAATAAAGCAACAAAGC), Ϫ1017a T (GAGGCAGGAGAATG-GTGTGAACCCGGGAGGC), Ϫ1017a C (GAGGCAGGAGAATGGC-GTGAACCCGGGAGGC), Ϫ145 C/Ϫ129 C (CTTTGCCACAGGAAGC-CTGA GCTCATTCGAGTAGCGGCTCTTCCAAG), Ϫ145 G/Ϫ129 T (CTTTGCCACAGGAAGGCTGAGCTCATTCGAGTAGCGGCTCTT-CCAAG) and Ϫ145 C/Ϫ129 C (CTTTGCCACAGGAAGCCTGAGCT-CATTCGAGCAGCGGCTCTTCCAAG) were synthesized with both sense and antisense strands, the corresponding pairs of which were annealed and end-labeled with T4 polynucleotide kinase (Takara) and [␥-32 P]dATP (Amersham Biosciences AB) according to standard methodology. The ␥-32 P-labeled probe (1 ϫ 10 4 cpm) was incubated for 30 min at 0°C with nuclear protein (5 g) in binding buffer (10 l) containing 25 mM Hepes (pH 7.9), 40 mM KCl, 5 mM MgCl 2 , 0.1 mM EDTA, 7.5% glycerol, 1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 0.1% Nonidet-40, 5 M ZnSO4, 0.2 g of poly(dI-dC), and 1 g of bovine albumin. Competitor oligonucleotides were added at 100-fold molar excesses. Reaction mixtures were electrophoresed on 5% polyacrylamide and 2.5% glycerol gel in a Tris-glycine-EDTA buffer (250 mM Tris, 1.9 M glycine, and 10 mM EDTA) at 4°C and visualized by a BAS-2500 Imaging Analyzer (Fuji Film, Tokyo, Japan).
Determination of Methylation. The methylation status of CpG sites within the proximal promoter region of MDR1 was confirmed using the bisulfite sequencing method (Frommer et al., 1992) . DNA was treated with sodium bisulfite using a CpGenome DNA modification kit (Intergen, Purchase, NY) according to the manufacturer's instructions. PCR (578 bp, Ϫ214a to Ex1/ϩ40) was performed in a total volume of 25 l consisting of 50 ng of bisulfite-modified genomic DNA, 0.625 to 2.5 U of Amplitaq Gold DNA polymerase, and 0.25 M of each primer, 5Ј-AAGGTGTTAGGAAGTAGAAAGGT-3Ј and 5Ј-AAA CTATCCCATAATAACTCCCAA-3Ј. After an initial denaturation at 95°C for 5 min, 35 cycles of 45 s at 95°C, 45 s at 55°C, and 1 min at 72°C, as well as a final extension period of 5 min at 72°C, were performed. The PCR product was cloned into the pGEM-T easy vector according to the manufacturer's instructions. The CpG methylation status of individual DNA strands was determined based on a comparison with the sequence obtained from the genomic DNA without the addition of bisulfite modifications. The number of methylated CpGs at a specific site was divided by the number of clones analyzed (N Ͼ 15) to yield percentage of methylation for each site.
Statistical Analysis. The 95% confidence interval was calculated to compare the differences in genotype or haplotype frequencies between Japanese and Caucasians. Results of MDR1 mRNA expression and mutation (C3435T) were analyzed with a Kruskal-Wallis test. Comparisons between two groups were performed using a Mann-Whitney U test. A 5% level of probability was considered to be significant.
Results

Identification of Variants in the Promoter
Region of the MDR1 Gene. Ten variants were detected in the promoter region of the human MDR1 gene by PCR-SSCP analysis using DNAs obtained from unrelated Japanese and Caucasian subjects ( Fig. 1; Table 1 ). Seven variants, at positions Ϫ1517a, Ϫ1459a, Ϫ1423a, Ϫ1132a, Ϫ1017a, Ϫ824a, and Ϫ755a, were newly identified in this study. The most common mutation in Japanese was G-1459aA (allelic frequency 0.250), whereas A-41aG (0.106), T-1517aC (0.080), T-1017aC (0.080), T-129C (0.080) were found at low frequency. The 5-base deletion at position -1132a to -1128a, C-145G and T-824aC were detected at extremely low frequency (0.037, 0.032, and 0.005, respectively). The frequencies of T-1017aC and T-129C were significantly lower in Caucasians than Japanese (P Ͻ 0.05). The two-base deletion at position Ϫ1423a to Ϫ1422a and A-755aG were identified only in Caucasian subjects, but at frequencies below 0.010. In contrast, T-1517aC, G-1459aA, a five-base deletion at position Ϫ1132a to Ϫ1128a, T-824aC, A-41aG, and C-145C were not detected in Caucasian subjects. These results indicate that genotypic frequencies of variants in the promoter region of the MDR1 gene seemed to be dependent on race.
Identification of MDR1 Promoter Haplotypes. On the basis of a haplotype analysis using subcloning and direct sequencing, 10 haplotypes derived from all identified promoter variants were found to be present in both populations (Table 2 ). In Japanese, seven haplotypes were identified with a frequency ranging from 0.005 to 0.665. Unlike in Caucasians, three variants at Ϫ1517a, Ϫ1017a, and Ϫ129 occurred simultaneously in Japanese. In total, 13 different haplotype pairs were found in the subjects examined (Table 3 ). In Caucasians, the most common haplotype pair was 1/1 (0.923). In contrast, hetero-or homogenous combinations of haplotypes with one or more variant sites were found at a relatively high frequency in Japanese compared with Caucasians (0.553 versus 0.077).
Association of MDR1 Promoter Haplotypes with mRNA Expression in Placenta and Liver. Before investigating the influence of MDR1 promoter haplotype combinations on mRNA expression in placental and hepatic tissues, we determined whether the C3435T variant influences MDR1 mRNA expression. As shown in Fig. 2 , the synonymous C3435T polymorphism in exon 26 was associated with a low level of placental MDR1 expression (P Ͻ 0.05; KruskalWallis test). Next, we compared MDR1 promoter haplotype pairs (haplotypes 1/1, 1/2, 1/3, 1/4, and 4/4) with corresponding placental and hepatic MDR1 levels in 29 and 11 samples with the 3435 C/C and C/T genotype, respectively (Fig. 2) . The MDR1 expression in placental tissue with haplotype 1/2 or 1/3 tended to increase compared with that in 1/1 samples (P ϭ 0.091; Mann-Whitney U test; Fig. 2 ). However, mean mRNA levels in hetero-and homogygous samples for haplotype 4 was comparable with those in 1/1 samples. Also, the MDR1 expression in hepatic tissue of haplotype 1/2 or 1/3 tended to increase compared with that in 1/1 samples (P ϭ 0.07; Mann-Whitney U test; Fig. 2) .
Luciferase Reporter Gene Assay. To investigate the influence of promoter haplotypes on the potential for transcriptional regulation, 10 reporter plasmids containing MDR1 promoter sequences were transiently transfected in HepG2 cells, and then luciferase activities were measured. As shown in Fig. 3 , haplotypes 2, 3, and 9 increased the luciferase activity by 41, 32, and 30%, respectively, compared with that by haplotype 1. In contrast, the haplotype 6 construct resulted in a 28% reduction in activity. Other haplotypes did not seem to influence the activity.
Binding of Nuclear Proteins to the Promoter Variant Sites. To determine whether the variants in the promoter
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at ASPET Journals on April 12, 2017 jpet.aspetjournals.org region altered binding for transcription factors, we performed EMSA using nuclear extracts prepared from HepG2 cells. By competition assays using an excess of unlabeled probe, allele-specific binding of nuclear proteins was observed when the nuclear extracts were incubated with probes, including Ϫ1517a C (complex I) and Ϫ1459a G (complex II) (Fig. 4, A and B) . Also, strong nuclear protein-DNA binding (complex III) was observed with the probe containing the Ϫ1017a T allele when compared with the Ϫ1017a C allele (Fig. 4C) . The higher binding completely disappeared under an excess of unlabeled Ϫ1017a T probe, and weaker inhibition of the binding was observed with the Ϫ1017a C probe. With the Ϫ145/Ϫ129 C/T and G/T probes, nuclear protein-DNA binding (complex VI) was detected, but with the C/C probe it was not detected or was much weaker (Fig. 4D) . The protein-DNA binding was completely inhibited by an excess of unlabeled C/T and G/T probes, and slightly competed with by an excess of unlabeled C/C probe. No nuclear protein-DNA binding was observed when the probes containing the Ϫ41a A/G and Ϫ145 G/C alleles were incubated with nuclear extracts.
Correlation between Placental MDR1 mRNA Expression and Methylation Status at CpG Sites in the MDR1 Promoter Region. The proximal region of the human MDR1 is rich in CpG (Fig. 5A ). This region including the Y box and GC box elements is required for activation of the MDR1 promoter. We focused on the CpG-rich proximal promoter region in the MDR1 gene and determined the relationship between methylation status at each CpG site and MDR1 mRNA expression using placenta with promoter haplotype 1/1 and 3435 C/C genotypes. Results of a bisulfite sequencing analysis of 26 CpG sites in seven subjects, whose MDR1 levels varied considerably, are shown in Fig. 5B . In all samples, methylated CpG sites were found upstream of the promoter region. Moreover, an interindividual difference in methylation status was observed; however, no clear associa- 
Discussion
Despite evidence supporting an association of coding SNPs with pharmacokinetics and pharmacodynamics, little is known about the presence or functional relevance of allelic variants in the promoter region of MDR1. We described 10 polymorphic variants in the MDR1 promoter in Japanese and Caucasian populations. A-41aG, C-145G, and T-129C have been detected in the proximal promoter region of the MDR1 gene as low frequency variants Tang et al., 2002; Kroetz et al., 2003) . Here, we identified another seven variants. Their presence and frequency varied according to race. For example, C-145G was identified in AsianAmericans but not Caucasians (Kroetz et al., 2003) . In the present study, this variant was observed only in Japanese. In addition, the new G-1459aA variant was the most frequent variant in Japanese (25.0%), but was not found in Caucasians.
The promoter region of the MDR1 gene has been isolated and sequenced (Ueda et al., 1987; Madden et al., 1993) . The promoter has an initiator sequence at the transcriptional start site, without a TATA box (van Groenigen et al., 1993) . Numerous studies have shown that the Y box (inverted CCAAT box) and GC box, recognized by the transcription factors NF-Y and Sp1, respectively, are required for efficient transcriptional regulation of the MDR1 promoter Sundseth et al., 1997) . Several studies suggest that a region upstream of the Y box negatively regulates the MDR1 promoter activity (Ogura et al., 1992; Cornwell and Smith, 1993) , although the exact positions of the negative element differ. However, our variants are not located within those cis-elements. We identified 10 different MDR1 promoter haplotypes using subcloning and direct sequencing methods. A comparison of MDR1 haplotype pairs with placental and hepatic expression showed that haplotypes 1/2 and 1/3 were associated with increased mRNA expression, independent of the C3435T mutation in the coding region. Interestingly, haplotypes 2 and 3, in which T-1517a C, T-1017aC, and T-129C mutations occurred simultaneously in both populations, were associated a Position is relative to the initiation site of exon 1a, which is defined as ϩ1a. b Reference sequence GenBank accession no. AC002457. c The 95% confidence intervals are given in parentheses. d Position is relative to the initiation site of translation, which is defined as ϩ1.
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with an increase in transcriptional activity in human hepatoma cell line. Moreover, we showed that the T-1517aC, T-1017aC, and T-129C variants affected putative transcriptional protein-DNA binding. Heterozygosity for the -129C allele is associated with a high level of transport activity of P-glycoprotein in hematopoietic stem cells (Calado et al., 2002) . The tacrolimus oral dose requirement is higher in renal transplant recipients with the T/C allele than T/T allele at position -129 (Anglicheau et al., 2003) . Although these findings are not significant because the T-129C variant was   TABLE 2 Localization of variants and identification of the MDR1 promoter haplotypes in Japanese and Caucasian subjects rare, the C allele at position -129 may be associated with high level of expression of P-glycoprotein, resulting in an increase in transport activity and then a decrease in tacrolimus bioavailability after oral administration. In contrast to these haplotypes, haplotype 6 (G-1459aA and C-145G variant) was associated with a low level of transcriptional activity in hepatoma cells. We found that the G-1459aA variant inhibits the binding of unknown transcriptional factor to DNA. Therefore, allelic variants not only in the coding region but also in the promoter region of the MDR1 gene, may be important to the interindividual difference in P-glycoprotein expression. We determined the interindividual difference in methylation status in the proximal promoter region of the MDR1 gene using seven placentas whose mRNA levels varied considerably. Extensive methylation of the MDR1 gene assembled into chromatin enriched with methylated CpG binding protein interfered with the binding of transcription factors to their elements, resulting in transcriptional repression of the gene (Jin and Scotto, 1998; El-Osta et al., 2002) . In this study, the region upstream of the promoter region was relatively well methylated, but individual differences in methylation status were unlikely to cause large variation in MDR1 mRNA expression. Nakayama et al. (1998) reported that methylation at CpG sites near the Y box was important for MDR1 gene expression and was associated closely with clinical outcome in acute myeloid leukemia. However, we did not find any methylation around either the Y box or GC box element. Similar results for methylation status in the promoter region have been reported in CD8-positive cells (Fryxell et al., 1999) . The element Sp1 protects the promoter from de novo methylation (Brandeis et al., 1994) . Macleod et al. (1994 Macleod et al. ( , 1998 have suggested that the presence of a functional element within the GC-rich domain maintains the methylation-free status. Accordingly, although the proximal promoter of the MDR1 gene is important for regulating basal gene expression in normal human tissues, epigenetic status jpet.aspetjournals.org seems not to be associated with variability in the transcriptional activity of the MDR1 gene.
In conclusion, we identified various variants in the promoter of the MDR1 gene and investigated their effects on transcriptional activity and mRNA expression in the placenta. Among these variants, the promoter haplotypes containing T-1517aC, T-1017aC, and T-129C were particularly associated with high level of transcriptional activity and mRNA expression but independently of the coding SNP C3435T. Because these promoter haplotypes or SNPs are found at a relatively low frequency in Japanese and Caucasian populations, further study is needed to establish the impact of their allelic variants on drug disposition and responses in clinical situations. Interestingly, one study has shown a possibility of regulation by tissue-specific factors for the MDR1 gene expression (Kohno et al., 1990) . Also, Sundseth et al. (1997) have reported that an element just upstream of the Y box had opposite effects in different human carcinoma cell lines. Their results suggest that allelic variants in the promoter region of the MDR1 gene contribute to the polymorphic expression of P-glycoprotein in a tissue-specific manner. Future studies may need to estimate the influence of MDR1 promoter variants on transcriptional activity in various P-glycoprotein-expressing tissues. 
